Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent

Journal of Human Hypertension

Volumn 11, Issue SUPPL. 1, 1997, Pages

  Prichard, B N C ^a   Owens, C W I ^a   Graham, B R ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Comparisons; Haemodynamics; Hypertension; Moxonidine; Pharmacology

Indexed keywords

6 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 1H 3 BENZAZEPINE; ADRENALIN; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EFAROXAN; IMIDAZOLINE I1 RECEPTOR; MOXONIDINE; NORADRENALIN; RENIN; UNINDEXED DRUG;

ANTIHYPERTENSIVE ACTIVITY; BIOTRANSFORMATION; BLOOD PRESSURE; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; DROWSINESS; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; HEADACHE; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE HYPERTROPHY; HEART OUTPUT; HEART RATE; HEART STROKE VOLUME; HEMODYNAMICS; HUMAN; HYPERTENSION; INTRACEREBRAL DRUG ADMINISTRATION; INTRACISTERNAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY DISEASE; LUNG ARTERY PRESSURE; MEDULLA OBLONGATA; META ANALYSIS; NONHUMAN; ORAL DRUG ADMINISTRATION; RECEPTOR AFFINITY; RECEPTOR BLOCKING; REVIEW; SIDE EFFECT; SYMPATHETIC TONE; SYSTEMIC VASCULAR RESISTANCE; XEROSTOMIA;

EID: 0030768503     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (78)

1. van Zwieten PA. Centrally acting antihypertensives: a renaissance of interest. Mechanisms and haemodynamics. J Hypertens 1997; 15 (Suppl 1): S3-S8.
2. Palatini P, Julius S. Association and tachycardia with morbidity and mortality: pathophysiological considerations. J Hum Hypertens 1997; 11 (Suppl 1): S19-S27.
3. Mancia G et al. Sympathetic activity, blood pressure variability and end organ damage in hypertension. J Hum Hypertens 1997; 11 (Suppl 1): S3-S8.
4. Pickering TG. The effects of environmental and life-style factors on blood pressure and the intermediary role of the sympathetic nervous system. J Hum Hypertens 1997; 11 (Suppl 1) S9-S18.
5. Langer SZ, Duval N, Massingham R. Pharmacologic and therapeutic significance of alpha-adrenoceptor subtypes. J Cardiovasc Pharmacol 1985; 7 (Suppl 8): S1.
6. 2-adrenoceptor changes in hypertension. J Cardiovasc Pharmacol 1987; 10 (Suppl 4): S68.
7. Langer SZ, Hicks PE. Alpha-adrenoceptor subtypes in blood vessels: Physiology and pharmacology. J Cardiovasc Pharmacol 1984; 6 (Suppl 4): S547.
8. 2-adrenoceptor. Trends Pharmacol Sci 1982; 3: 440.
9. 1-adrenoceptors in the control of the autonomic nervous system in normotensive and spontaneously hypertensive rats. Eur J Pharmacol 1982; 85: 239.
10. 3H]dihydroazapetine to alpha adrenoceptor related proteins from rat vas deferens. Proc Natl Acad Sci USA 1976; 73: 2730-2734.
11. Ruffolo RR, Turowski BS, Patil PN. Lack of cross desensitisation between structurally dissimilar α-adrenoceptor agonists. J Pharm Pharmacol 1977; 29: 378-380.
12. 2-adrenergic effects of phenylethylamines and imidazoles. Eur J Pharmacol 1983; 86: 471-475.
13. Bousquet P, Feldman J, Schwartz J. Central cardiovascular effects of alpha adrenergic drugs. Differences between catecholamines and imidazolines. J Pharmacol Exp Ther 1984; 253: 232-236.
14. Armah BI, Hofferber E, Stenzel W. General pharmacology of the novel centrally acting antihypertensive agent moxonidine. Drug Research 1988; 38: 1426-1434.
15. Reis DJ, Regunathan S, Meeley MP. Imidazole receptors and clonidine-displacing substance in relationship to control of blood pressure, neuroprotection and adrenomedullary secretion. Am J Hypertens 1992; 5: 51S-57S
16. Hamilton CA. Adrenergic and non-adrenergic effects of imidazoline and related antihypertensive drugs in the brain and periphery. Am J Hypertens 1992: 5: 58S.
17. 1-imidazoline receptors in the rostral ventrolateral medulla. J Cardiovasc Pharmacol 1994; 24 (Suppl 1): S1-S8.
18. 2-agonists. J Cardiovasc Pharmacol 1985; 7 (Suppl 8): S38.
19. Guyenet PG, Cabot JB. Inhibition of sympathetic preganglionic neurones by catecholamines and clonidine: Mediation by an alpha-adrenergic receptor. J Neurosci 1981; 1: 908.
20. Reid JL et al. The central hypotensive effect of clonidine: Studies in tetraplegic subjects. Clin Pharmacol Ther 1977; 21: 375-381.
21. 1 receptor and the pharmacology of imidazolines. Cardiovasc Drug Ther 1994; 8 (Suppl 1): S21-S26.
22. Klepzig H et al. Akuter und chronischer Einfluß von Moxonidin auf Blutdruck und linksventrikuläre Funktion in Ruhe und unter Belastung. In: Hayduk K, Stumpe KO (eds). Ein neues Therapieprinzip zur Behandlung der Hypertonie 1992, pp 23-30.
23. Cheung DG, Burris JF, Graettinger WF, Weber MA. Clonidine. In: Messerli FH (ed). Cardiovascular Drug Therapy. 2nd Ed. WB Saunders Company; USA, 1996, pp 622-628.
24. 1-imidazoline receptor agonist. J Cardiovasc Pharmacol 1996; 27 (Suppl 3): S26-S37.
25. Rupp H, Dhalla KS, Dhalla NS. Mechanisms of cardiac cell damage due to catecholamines: significance of drugs regulating central sympathetic outflow. J Cardiovasc Pharmacol 1994; 24 (Suppl 1): S16-S24.
26. Ernsberger P, Giuliano R, Willette RN, Reis DJ. Role of imidazole receptors in the vasodepressor response to clonidine analogs in the rostral ventrolateral medulla. J Pharmacol Exp Ther 1990; 253: 408-418.
27. 1-Imidazoline sites. J Pharmacol Exp Ther 1993; 264: 172-182.
28. Dominiak P, Keogh JP, Prichard BNC. Moxonidine. In: Messerli FH (ed). Cardiovascular Drug Therapy. 2nd Ed. WB Saunders Company; USA, 1966, pp 651-661.
29. Allan DR, Penner SB, Smyth DD. Renal imidazoline preferring sites and solute excretion in the rat. Br J Pharmacol 1993; 108: 870-875.
30. 1-imidazoline receptor agonist, moxonidine. Br J Pharmacol 1994; 112: 1089-1094.
31. 1-imidazoline preferring receptors: two unique sites mediating naturesis in the rat. Cardiovasc Drugs Ther 1994; 8: 43-48.
32. Irzyniec T, Mall G, Greber D, Ritz E. Beneficial effect of nifedipine and moxonidine on glomerulosclerosis in spontaneously hypertensive rats. A micromorphometric study. Am J Hypertens 1992; 5: 437-443.
33. Lepran I, Papp JG. Effect of moxonidine on arrhythmias induced by coronary artery occlusion and reperfusion. J Cardiovasc Pharmacol 1994; 24 (Suppl 1): S9-S15.
34. Mall G et al. Effects of nifedipine and moxonidine on cardiac structure in spontaneously hypertensive rats (SHR) - stereological studies on myocytes, capillaries, arteries, and cardiac interstitium. Basic Res Cardiol 1991; 86 (Suppl 3): 33-44.
35. MacPhee GJA, Howie CA, Elliott HL, Reid JL. A comparison of the haemodynamic and behaviourial effects of moxonidine and clonidine in normotensive subjects. Br J Clin Pharmacol 1992; 33: 261-267.
36. Kirch H, Hutt H-I, Plänitz V. Pharmacodynamic action and pharmacokinetics of moxonidine after single oral administration in hypertensive patients. J Clin Pharmacol 1990; 30: 1088-1095.
37. Mitrovic V, Patyna W, Hüting J, Schlepper M. Hemodynamic and neurohumoral effects of moxonidine in patients with essential hypertension. Cardiovasc Drugs Ther 1991; 5: 967-972.
38. Mitrovic V, Patyna WD, Yahya H, Schlepper M. Einfluss des Imidazolrezeptoragonisten Moxonidin auf die zentrale und periphere Hämodynamik bei Patienten mit essentieller Hypertonie. Interlaken. Joint Meeting Swiss and German Society of Cardiology, April 1994.
39. Hüting J, Mitrovic V, Bahavar H, Schlepper M. Vergleich der Wirkungen von Moxonidin und Nifedipin auf die linksventrikuläre Funktion bei Monotherapie der essentiellen Hypertonie. Herz Kreislauf 1992; 24: 132-137.
40. Eichstädt H et al. Demonstration of hypertrophy regression with magnetic resonance tomography under the new adrenergic inhibitor moxonidine. Cardiovasc Drugs Ther 1989; 3 (Suppl 2): 583-587.
41. Eichstädt H, Gatz G, Schröder R, Kreuz D. Linksventrkuläre Hypertrophieregression unter einer Therapie mit Moxonidin. J Pharmacol Ther 1991; 1: 12-17.
42. Motz W, Vogt M, Scheler S, Strauer BE. Hypertensive coronary microcirculation effects of the imidazoline-receptor-agonist moxonidine. Cardiovasc Risk Factors 1995; 5 (Suppl 1): 28-32.
43. Wenzel RR et al. Moxonidine decreases muscle sympathetic nerve activity (MSA) in patients with untreated hypertension. Hospitalis 1997; 67: 13.
44. Schmidt U et al. Hypertension: A possible risk in road traffic. J Cardiovasc Pharmacol 1992; 20 (Suppl 4): S50-S56.
45. Fliser D, Wiecek A, Ritz E. Renal hemodynamics. Cardiovasc Risk Factors 1995; 5 (Suppl 1): S40-S44.
46. DeFronzo RA. Insulin resistance, hyperinsulinemia, and coronary artery disease: A complex metabolic web. J Cardiovasc Pharmacol 1992; 20 (Suppl 11): S1-S16.
47. Prichard BNC, Smith CCT, Sen S, Betteridge DJ. Hypertension and insulin resistance. J Cardiovasc Pharmacol 1992: 20 (Suppl 11): S77-S84.
48. Kaan EC et al. Effects of agmatine and moxonidine on glucose metabolism: An integrated approach towards pathophysiological mechanisms in cardiovascular metabolic disorders. Cardiovasc Risk Factors 1995; 5 (Suppl 1): 19-27.
49. Löw-Kröger A, Rosenthal J. Antihypertensive Therapie mit Moxonidin: Bestätigung des Imidazolinrezeptor-agonisten in der breiten Anwendung. Herz/Kreisl 1994; 26: 206-211.
50. 1 receptor agonist moxonidine in patients with idiopathic dilated cardiomyopathy and heart failure. Eur J Clin Res 1996; 8: 149-161.
51. 2-adrenergic agonist moxonidine on anterior pituitary hormone secretion in comparison to clonidine and GHRH. Acta Endocrinol 1989; 120 (Suppl 1): 80-84.
52. Theodor RA, Weimann HJ, Weber W, Michaelis K. Absolute bioavailability of moxonidine. Eur J Drug Metab Pharmacokinet 1991; 16: 153-159.
53. Weimann HJ, Rudolph M. Clinical pharmacokinetics of moxonidine. J Cardiovasc Pharmacol 1992; 20 (Suppl 4): S37-S41.
54. Kirch H, Hutt H-J, Plänitz V. The influence of renal function on clinical pharmacokinetics of moxonidine. Clin Pharmacokinet 1988; 15: 245-253.
55. Theodor RA et al. Age-related effects on the pharmacokinetics of moxonidine. Eur J Clin Res 1996; 8: 63-74.
56. Klink F. Clinical investigation of the passage of moxonidine from the maternal blood stream to the breast milk in patients with hypertension. Beiersdorf AG Study No. 200 029-5895-2228-52, 1990.
57. 2-adrenoreceptor agonist in arterial essential hypertension. Clinical experience with moxonidine. Curr Ther Res 1987; 42: 138-146.
58. Plänitz V, Kandziora J. Wirksamkeit und Verträglichkeit des neuen Antihypertensivums Moxonidin bei vorwiegend älteren Patienten. Therapiewoche 1984; 34: 6426.
59. Schwartz VW, Kandziora J. Langzeiterfahrungen mit Moxonidin, einem neuen Antihypertensivum. Fortschritte der Medizin 1990; 108: 64-70.
60. 1 receptor agonist moxonidine in patients with mild to moderate essential hypertension. Eur J Clin Res 1995; 7: 227-240.
61. Küppers HE et al. Placebo-controlled comparison of the efficacy and tolerability of once-daily moxonidine and enalapril in mild-to-moderate essential hypertension. J Hypertens 1997; 15: 93-97.
62. Plänitz V. Comparison of moxonidine and clonidine HCl in treating patients with hypertension. J Clin Pharmacol 1987; 27: 46-51.
63. Plänitz V. Intra-individual comparison of moxonidine and prazosin in hypertensive patients. Eur J Clin Pharmacol 1986; 29: 645-650.
64. Wolf R. The treatment of hypertensive patients with a calcium antagonist or moxonidine: a comparison. J Cardiovasc Pharmacol 1992; 20 (Suppl 4): S42-S44.
65. Lotti G, Gianrossi R. Moxonidin versus Captopril bei leichter bis mittelschwerer Hypertonie. Fortschritte der Medizin 1993; 111: 429.
66. Ollivier JP, Christen MO, Schäfer SG. Moxonidine: a second generation of centrally acting drugs. An appraisal of clinical experience. J Cardiovasc Pharmacol 1992; 20 (Suppl 4): S31-S37.
67. Kraft K, Vetter H. Twenty-four-hour blood pressure profiles in patients with mild-to-moderate hypertension: moxonidine versus captopril. J Cardiovasc Pharmacol 1994; 24: S29-S33.
68. Schäfers RF, Löw-Kröger A, Philipp T. Wirksamkeit und Verträglichkeit des neuen zentralwirksamen Antihypertensivums Moxonidin im Vergleich zu Enalapril. Nieren und Hochdruckkrankheiten 1994; 5: S221-224.
69. Prichard BNC et al. A double-blind comparison of moxonidine and atenolol in the management of patients with mild-to-moderate hypertension. J Cardiovasc Pharmacol 1992; 20 (Suppl 4): 545-549.
70. Larrat V. Efficacy and tolerance of moxonidine in comparison with a standard therapy with hydrochlorothiazide. Beiersdorf AG. Report No. 200.029-28-54, 1990.
71. Frei M et al. Moxonidine and hydrochlorothiazide in combination: a synergistic antihypertensive effect. J Cardiovasc Pharmacol 1994; 24 (Suppl 1): S25-S28.
72. Kaan EC, Jäger BA, Verbcom C, Prichard BNC. An analysis of the spectrum of activity of moxonidine, 1997; In preparation.
73. Wilkens H, Wilkens JH, Fabel H. Die Wirkung von Moxonidin - einem zentral wirksamen Antihypertensivum - auf Atemregulation und Histaminreaktivität. Kardio 1992, 10(11): 1-4.
74. 2-Adrenozeptor-Agonisten bei Patienten mit arterieller Hypertonie. Cor Vas 1991; 5 (Part 3): 1-12.
75. Webster J, Koch HF. Aspects of tolerability of centrally acting antihypertensive drugs. J Cardiovasc Pharmacol 1996; 26 (Suppl 3): S49-S54.
76. Ongyert D, Dotzer F. Wirksamkeit und Verträglichkeit von Moxonidin. Zeit Allgemeinmed 1993; 69: S56-S60.
77. Plänitz V. Crossover comparison of moxonidine and clonidine in mild to moderate hypertension. Eur J Clin Pharmacol 1984; 27: 147-152.
78. 1-imidazoline receptors. J Cardiovasc Pharmacol 1992; 20 (Suppl 4): S1-S10.